[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558455":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":45,"collaborators":18,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":18,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Queen Mary Hospital, Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin D replacement","ACTIVE_COMPARATOR","Those with vitamin D deficiency will be replaced with vitamin D3 at 1000 IU at the first visit. Vitamin D3 1000 IU is expected to increase blood 25-hydroxyvitamin-D level by 25 nmol\u002FL. Blood 25-hydroxyvitamin-D level will be rechecked 3 months after replacement. If the blood 25-hydroxyvitamin-D level is still below 50 nmol\u002FL, the vitamin D3 replacement dosage will be increased to 2000 IU.",[13],"Drug: Vitamin D3",{"label":15,"type":16,"description":17,"interventionNames":18},"Vitamin D non-deficiency","NO_INTERVENTION","No drug will be given to patients with Vitamin D non-deficiency.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Vitamin D3","The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Wang Chun Kwok, MBBS","CONTACT","2255 3111","kwokwch@hku.hk",[32],{"facility":33,"status":34,"city":35,"state":18,"zip":18,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Queen Mary Hospital","RECRUITING","Hong Kong","HK",{"type":38,"coordinates":39},"Point",[40,41],114.17469,22.27832,{"lat":41,"lon":40},[44],{"name":27,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":49,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Kwok Wang Chun","Clinical Assistant Professor","The University of Hong Kong","100558455","phase-4-vitamin-d-replacement-in-bronchiectasis-100558455",false,"NCT06551337","Vitamin D Replacement in Bronchiectasis","Prospective Clinical Study on Vitamin D Replacement in Bronchiectasis - A Pilot Study","Inclusion Criteria:\n\n1. ages 18 years or above, male or female.\n2. confirmed diagnosis of non-CF bronchiectasis based on high-resolution computed tomography (HRCT) scan.\n3. participation in the prior study entitled \"Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation\" (UW 22-317)\n\nExclusion Criteria:\n\n1. underlying asthma, COPD and other co-existing respiratory diseases\n2. underlying osteoporosis\n3. supplementary Vitamin D in their regimen\n4. advanced chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 30mL\u002Fmin","ALL","18 Years",{"count":60,"type":61},104,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","This study seeks to address the limitations in previous related studies on vitamin D replacement and bronchiectasis exacerbation occurrence through a self-controlled pilot study. The investigators aim to investigate whether vitamin D replacement in bronchiectasis patients with vitamin D deficiency can reduce hospitalized bronchiectasis exacerbation occurrence. Patients who participated in the prior study entitled \"Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation\" (UW 22-317) will be invited for participation during regular clinic follow-up and management in Queen Mary Hospital. If participants are willing to join the further research, participants will be recruited in this self-controlled study. There are some differences from usual management to non-CF bronchiectasis subjects. The study subjects would be checked for their blood 25-hydroxyvitamin-D level during the study period. The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU (if needed). The investigators aim to correct their Vitamin D deficiency completely, aiming at blood 25-hydroxyvitamin-D level \\>=50, i.e. treat to target. The dose depends on the level of Vitamin D after replacement. If blood 25-hydroxyvitamin-D level is 50 or above, then 1000 IU is suffice. If blood 25-hydroxyvitamin-D level is still below 50, the investigators will increase to 2000 IU.",[67],"Bronchiectasis","2024-08-09",{"date":70,"type":71},"2024-08-13","ACTUAL",{"date":73,"type":71},"2024-04-17",{"date":75,"type":61},"2027-06-30",{"name":5,"class":6},1]